Amgen

“The gold rush led by Big Pharma and investors has ended. The market is punishing developers whose drugs fail to stand out, and pipelines are being trimmed. Pfizer just axed another program from its massive Metsera deal, while peers like Amgen have begun trimming their own early-stage pipelines.”

“It was either Amgen or Gilead did it first... then the actual price on the drug that is paid by the insurers, the net price, came down immediately. Because when you have like 10 drugs in a space, the cost of the drug is like 90% down.”